

Understanding Liver Cancer: A Tale of Two Diseases


Brian I. Carr, MD, FRCP, PhD

Director, Liver Cancer Program

IRCCS de Bellis Medical Center

Castellana Grotte BA

Italy



Understanding Liver Cancer: A Tale of Two Diseases

Understanding Liver Cancer: A Tale of Two Diseases

Brian I. Carr, MD, FRCP, PhD

Director, Liver Cancer Program

IRCCS de Bellis Medical Center

Castellana Grotte BA

Italy

Published by Springer Healthcare Ltd, 236 Gray's Inn Road, London, WC1X 8HB, UK.

www.springerhealthcare.com

©2014 Springer Healthcare, a part of Springer Science+Business Media.

ISBN 978-1-910315-01-9

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the copyright holder.

Although every effort has been made to ensure that drug doses and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician. Neither the publisher nor the authors can be held responsible for errors or for any consequences arising from the use of the information contained herein. Any product mentioned in this publication should be used in accordance with the prescribing information prepared by the manufacturers. No claims or endorsements are made for any drug or compound at present under clinical investigation.

Project editor: Tess Salazar

Production manager: Patty Goldstein

Printed in Great Britain by Latimer Trend

Contents

Dedications	vii
Author biography	ix
Abbreviations	xi
Foreword	xiii
Preface	xv
Section 1. Introduction to hepatocellular carcinoma	1
Introduction	1
Incidence and geography	2
Causes of hepatocellular carcinoma	4
Prevention	8
Surveillance screening	10
Biology of human hepatocellular carcinoma	11
Section 2. Clinical disease evaluation	17
Diagnosis A: Radiology	17
Diagnosis B: Blood tests, tumor markers	18
Diagnosis C: Biopsy – a debate	19
Assessment of tumor extent for treatment planning: staging classifications	20
The new patient assessment	22
Section 3. Management of hepatocellular carcinoma	25
General treatment choices	27
Therapies with curative intent	31
Non-curative therapies	34
Systemic drugs	37
Assessment of responses to therapy: what do tumor size responses signify?	40
Hepatitis therapy is also anticancer therapy	43
Section 4. The whole patient setting	45
Therapy decisions for the individual patient:	
importance of a multidisciplinary team approach	45
Psychosocial considerations, family, support groups	46
Section 5. New directions	47
Section 6. Addendum	49
Abbreviations, extended	50

“Everything should be made as simple as possible, but not simpler.”

- Albert Einstein

“Truth does not become more true by virtue of the fact that the entire world agrees with it, nor less so even if the whole world disagrees with it.”

- Maimonides, *The Guide for the Perplexed*

“Scientific knowledge is in perpetual evolution; it finds itself changed from one day to the next.”

- Jean Piaget

For my children: Ophira and Rajeev, Feridey and Mike

And their children: Rohan, Kunal and Oren